Larimar Therapeutics (STU:ZA71) Total Stockholders Equity : €133.45 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Total Stockholders Equity?

Larimar Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €133.45 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Larimar Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was €2.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Larimar Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.03.

Larimar Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Larimar Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Total Stockholders Equity Chart

Larimar Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

73.73

57.01

104.69

74.94

164.08

Larimar Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															212.38	196.39	178.76	164.08	133.45

Larimar Therapeutics (STU:ZA71) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Larimar Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(133.451	-	0)	/	64.028
	=	2.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Larimar Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.014	+	3.487)	/	133.451
	=	0.03

Larimar Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Larimar Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

LRMR:USA

Address

Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004

Website

https://www.larimartx.com

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines